98%
921
2 minutes
20
Synovial sarcoma (SyS) is an aggressive mesenchymal malignancy invariably associated with the chromosomal translocation t(X:18; p11:q11), which results in the in-frame fusion of the BAF complex gene to one of three genes. Fusion of SS18 to SSX generates an aberrant transcriptional regulator, which, in permissive cells, drives tumor development by initiating major chromatin remodeling events that disrupt the balance between BAF-mediated gene activation and polycomb-dependent repression. Here, we developed SyS organoids and performed genome-wide epigenomic profiling of these models and mesenchymal precursors to define SyS-specific chromatin remodeling mechanisms and dependencies. We show that SS18-SSX induces broad BAF domains at its binding sites, which oppose polycomb repressor complex (PRC) 2 activity, while facilitating recruitment of a non-canonical (nc)PRC1 variant. Along with the uncoupling of polycomb complexes, we observed H3K27me3 eviction, H2AK119ub deposition and the establishment of de novo active regulatory elements that drive SyS identity. These alterations are completely reversible upon SS18-SSX depletion and are associated with vulnerability to USP7 loss, a core member of ncPRC1.1. Using the power of primary tumor organoids, our work helps define the mechanisms of epigenetic dysregulation on which SyS cells are dependent.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768195 | PMC |
http://dx.doi.org/10.26508/lsa.202000808 | DOI Listing |
Front Oncol
August 2025
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Introduction: Synovial sarcoma (SS) is one of the most prevalent malignant soft tissue sarcomas in children and adolescents. Pediatric populations often present with atypical features, complicating the differentiation from benign intramuscular venous malformations (VMs).
case Presentation: An 11-year-old male with a four-year history of progressive right plantar pain and a compressible intramuscular mass.
Case Rep Pathol
September 2025
Faculty of Medicine, KCMC University, Moshi, Tanzania.
Synovial sarcomas are rare malignant soft tissue tumors with significant metastatic potential. Although they can occur in various parts of the body, they are most commonly found on the extremities. These tumors typically develop in children and young adults, making occurrences in individuals over 50 years of age unusual.
View Article and Find Full Text PDFBackground: Sarcomas of the trunk and abdominal wall are rare and present unique challenges in both resection with free margins and reconstruction, particularly when the tissue loss is extensive. These tumors predominantly affect young, active individuals, posing a significant challenge for oncologists and plastic surgeons in preserving the patients' quality of life.
Case Presentation: We present the case of 23-year-old woman with no significant medical history.
Oncogene
August 2025
Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
The SS18::SSX oncogene is the driver of synovial sarcoma, an aggressive cancer presenting in young adults that has poor long-term outcomes. Over the past five years, significant progress has been made in understanding the molecular, genomic, and epigenetic mechanisms underlying synovial sarcoma. This review synthesizes recent advancements in synovial sarcoma, including diagnostic pathology, genomic profiling, SS18::SSX biology, epigenetic dysregulation, proteomics, targetable pathways and immunotherapy.
View Article and Find Full Text PDFJ Clin Pathol
August 2025
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Aims: To investigate immunohistochemical expression of the E26 transformation-specific factors (ETS)-related gene () in a large number of soft tissue neoplasms using a tissue microarray technique.
Methods: 489 cases of soft tissue neoplasms, including benign and malignant entities, were collected from the files of the respective institutions and constructed into tissue microarrays. Tissue microarrays were stained for ERG immunohistochemistry using two antibodies, EP111 and EPR3864.